Ross E. B. Fitzsimmons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ross E. B. Fitzsimmons has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Craig A. Simmons
University of Toronto
2 shared publications - Hasan Uludağ
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
2 shared publications Adetola Adesida
Department of Biomedical Engineering, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada; Department of Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada
1 shared publicationAgnes Soos
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada
1 shared publication- Agnes Soos
Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College Street, Toronto, ON, Canada M5S 3G9
1 shared publication Aileen Zhong
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- 26 February 2021
- Published by IOP Publishing in Biomedical Materials
- Vol. 16 (3) , 035005
Assessment of fibrin-collagen co-gels for generating microvessels ex vivo using endothelial cell-lined microfluidics and multipotent stromal cell (MSC)-induced capillary morphogenesis
One aspect of the challenge of engineering viable tissues ex vivo is the generation of perfusable microvessels of varying diameters. In this work, we take the approach of using hydrogel-based microfluidics seeded with endothelial cells (ECs) to form small artery/vein-like vessels, in conjunction with using the self-assembly behavior of ECs to form capillary-like vessels when co-cultured with multipotent stromal cells (MSCs). In exploring this approach, we focused on investigating collagen, fibrin, and various collagen-fibrin co-gel formulations for their potential suitability as serving as scaffold materials by surveying their angiogencity and mechanical properties. Fibrin and co-gels successfully facilitated multicellular EC sprouting, whereas collagen elicited a migration response of individual ECs, unless supplemented with the protein kinase C (PKC)-activator, phorbol 12-myristate 13-acetate. Collagen scaffolds were also found to severely contract when embedded with mesenchymal cells, but this contraction could be abrogated with the addition of fibrin. Increasing collagen content within co-gel formulations, however, imparted a higher compressive modulus and allowed for the reliable formation of intact hydrogel-based microchannels which could then be perfused. Given the bioactivity and mechanical benefits of fibrin and collagen, respectively, collagen-fibrin co-gels are a promising scaffold option for generating vascularized tissue constructs.
- 26 February 2021
- Published by IOP Publishing in Biomedical Materials
- Vol. 16 (3) , 035005
Assessment of fibrin-collagen co-gels for generating microvessels ex vivo using endothelial cell-lined microfluidics and multipotent stromal cell (MSC)-induced capillary morphogenesis
One aspect of the challenge of engineering viable tissues ex vivo is the generation of perfusable microvessels of varying diameters. In this work, we take the approach of using hydrogel-based microfluidics seeded with endothelial cells (ECs) to form small artery/vein-like vessels, in conjunction with using the self-assembly behavior of ECs to form capillary-like vessels when co-cultured with multipotent stromal cells (MSCs). In exploring this approach, we focused on investigating collagen, fibrin, and various collagen-fibrin co-gel formulations for their potential suitability as serving as scaffold materials by surveying their angiogencity and mechanical properties. Fibrin and co-gels successfully facilitated multicellular EC sprouting, whereas collagen elicited a migration response of individual ECs, unless supplemented with the protein kinase C (PKC)-activator, phorbol 12-myristate 13-acetate. Collagen scaffolds were also found to severely contract when embedded with mesenchymal cells, but this contraction could be abrogated with the addition of fibrin. Increasing collagen content within co-gel formulations, however, imparted a higher compressive modulus and allowed for the reliable formation of intact hydrogel-based microchannels which could then be perfused. Given the bioactivity and mechanical benefits of fibrin and collagen, respectively, collagen-fibrin co-gels are a promising scaffold option for generating vascularized tissue constructs.
- Open Access
- 19 August 2018
- Published by Wiley in Stem Cells International
- Vol. 2018, 1-16
Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering
As a result of over five decades of investigation, mesenchymal stromal/stem cells (MSCs) have emerged as a versatile and frequently utilized cell source in the fields of regenerative medicine and tissue engineering. In this review, we summarize the history of MSC research from the initial discovery of their multipotency to the more recent recognition of their perivascular identityin vivoand their extraordinary capacity for immunomodulation and angiogenic signaling. As well, we discuss long-standing questions regarding their developmental origins and their capacity for differentiation toward a range of cell lineages. We also highlight important considerations and potential risks involved with their isolation, ex vivo expansion, and clinical use. Overall, this review aims to serve as an overview of the breadth of research that has demonstrated the utility of MSCs in a wide range of clinical contexts and continues to unravel the mechanisms by which these cells exert their therapeutic effects.
- 19 August 2018
- Published by Wiley in Stem Cells International
- Vol. 2018, 1-16
Open AccessMesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering
As a result of over five decades of investigation, mesenchymal stromal/stem cells (MSCs) have emerged as a versatile and frequently utilized cell source in the fields of regenerative medicine and tissue engineering. In this review, we summarize the history of MSC research from the initial discovery of their multipotency to the more recent recognition of their perivascular identityin vivoand their extraordinary capacity for immunomodulation and angiogenic signaling. As well, we discuss long-standing questions regarding their developmental origins and their capacity for differentiation toward a range of cell lineages. We also highlight important considerations and potential risks involved with their isolation, ex vivo expansion, and clinical use. Overall, this review aims to serve as an overview of the breadth of research that has demonstrated the utility of MSCs in a wide range of clinical contexts and continues to unravel the mechanisms by which these cells exert their therapeutic effects.
- 1 March 2018
- Published by Elsevier in Bioprinting
- Vol. 9, 7-18
Generating vascular channels within hydrogel constructs using an economical open-source 3D bioprinter and thermoreversible gels
- 1 March 2018
- Published by Elsevier in Bioprinting
- Vol. 9, 7-18
Generating vascular channels within hydrogel constructs using an economical open-source 3D bioprinter and thermoreversible gels
- 1 November 2012
- Published by Elsevier in Acta Biomaterialia
- Vol. 8 (11) , 3941-3955
Specific effects of PEGylation on gene delivery efficacy of polyethylenimine: Interplay between PEG substitution and N/P ratio
- 1 November 2012
- Published by Elsevier in Acta Biomaterialia
- Vol. 8 (11) , 3941-3955
Specific effects of PEGylation on gene delivery efficacy of polyethylenimine: Interplay between PEG substitution and N/P ratio
- Open Access
- 4 June 2012
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 7 (5) , 371-382
Effect of basic fibroblast growth factor in mouse embryonic stem cell culture and osteogenic differentiation
Embryonic stem cells are actively explored as a cell source in tissue engineering and regenerative medicine involving bone repair. Basic fibroblast growth factor (bFGF) has been a valuable growth factor to support the culture of human stem cells as well as their osteogenic differentiation, but the influence of bFGF on mouse embryonic stem (mES) cells is not known. Towards this goal, D3 cells were treated with bFGF during maintenance conditions and during spontaneous and osteogenic differentiation. In feeder-free monolayers, up to 40 ng/ml of exogenous bFGF did not support self-renewal of mES without LIF during cell expansion. During spontaneous differentiation in high-density cultures, bFGF stimulated cell proliferation under certain conditions but did not influence differentiation, as judged by stage-specific embryonic antigen-1 expression. The addition of bFGF reduced the alkaline phosphatase (ALP) activity associated with osteoblast activity during differentiation induced by osteogenic supplements, although the extent of mineralization was unaffected by bFGF. The bFGF increased the mesenchymal stem cell marker Sca-1 in an mES cell population and led to an enhanced increase in osteocalcin and runx2 expression in combination with BMP-2. These results suggest that bFGF could be utilized to expand the cell population in high-density cultures in addition to enriching the BMP-2 responsiveness of mES cells. Copyright © 2012 John Wiley & Sons, Ltd.
- 4 June 2012
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 7 (5) , 371-382
Open AccessEffect of basic fibroblast growth factor in mouse embryonic stem cell culture and osteogenic differentiation
Embryonic stem cells are actively explored as a cell source in tissue engineering and regenerative medicine involving bone repair. Basic fibroblast growth factor (bFGF) has been a valuable growth factor to support the culture of human stem cells as well as their osteogenic differentiation, but the influence of bFGF on mouse embryonic stem (mES) cells is not known. Towards this goal, D3 cells were treated with bFGF during maintenance conditions and during spontaneous and osteogenic differentiation. In feeder-free monolayers, up to 40 ng/ml of exogenous bFGF did not support self-renewal of mES without LIF during cell expansion. During spontaneous differentiation in high-density cultures, bFGF stimulated cell proliferation under certain conditions but did not influence differentiation, as judged by stage-specific embryonic antigen-1 expression. The addition of bFGF reduced the alkaline phosphatase (ALP) activity associated with osteoblast activity during differentiation induced by osteogenic supplements, although the extent of mineralization was unaffected by bFGF. The bFGF increased the mesenchymal stem cell marker Sca-1 in an mES cell population and led to an enhanced increase in osteocalcin and runx2 expression in combination with BMP-2. These results suggest that bFGF could be utilized to expand the cell population in high-density cultures in addition to enriching the BMP-2 responsiveness of mES cells. Copyright © 2012 John Wiley & Sons, Ltd.
- 1 January 2012
- Published by Elsevier in Developmental Biology
- Vol. 361 (2) , 412-426
The PP1 phosphatase Flapwing regulates the activity of Merlin and Moesin in Drosophila
- 1 January 2012
- Published by Elsevier in Developmental Biology
- Vol. 361 (2) , 412-426
The PP1 phosphatase Flapwing regulates the activity of Merlin and Moesin in Drosophila
- 3 October 2011
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 53 (2) , 117-131
Osteogenic Differentiation of Human Mesenchymal Stem Cells Cultured with Dexamethasone, Vitamin D3, Basic Fibroblast Growth Factor, and Bone Morphogenetic Protein-2
Purpose: Human mesenchymal stem cells (hMSCs) are pursued for cell-based therapies of bone defects. Successful use of hMSCs will require them to be osteogenically differentiated before transplantation. This study was intended to determine the optimal combination(s) of supplements needed for inducing osteogenesis in hMSCs. Methods: The hMSCs were cultured with combinations of β-glycerophosphate, dexamethasone (Dex), vitamin D3 (Vit-D3), basic fibroblast growth factor (bFGF), and bone morphogenetic protein-2 (BMP-2) to assess cell growth and osteogenesis. Osteogenic responses of the supplements were evaluated by alkaline phosphatase (ALP) activity, mineralization, and gene expression of ALP, Runx2, bone sialoprotein, and osteonectin. Adipogenesis was characterized based on Oil Red O staining, gene expression of peroxisome proliferator-activated receptor γ2, and adipocyte protein-2. Results: Dex was found to be essential for mineralization of hMSCs. Cultures treated with Dex (100 nM), Vit-D3 (10/50 nM), and BMP-2 (500 ng/mL) demonstrated maximal calcification and up-regulation of ALP and bone sialoprotein expression. However, adipogenesis was up-regulated in parallel with osteogenesis in these cultures, as evident by the presence of lipid droplets and significant up-regulation of peroxisome proliferator-activated receptor γ2 and adipocyte protein-2 expression. An optimal condition was obtained at Dex (10 nM) and BMP-2 (500 ng/mL) for mineralization without increasing adipogenesis-related markers. The bFGF mitigated osteogenesis and enhanced adipogenesis. Vit-D3 appears essential for calcification only in the presence of bFGF. Conclusion: Treatment of hMSCs with appropriate supplements at optimal doses results in robust osteogenic differentiation with minimal adipogenesis. These findings could be used in the cultivation of hMSCs for cell-based strategies for bone regeneration.
- 3 October 2011
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 53 (2) , 117-131
Osteogenic Differentiation of Human Mesenchymal Stem Cells Cultured with Dexamethasone, Vitamin D3, Basic Fibroblast Growth Factor, and Bone Morphogenetic Protein-2
Purpose: Human mesenchymal stem cells (hMSCs) are pursued for cell-based therapies of bone defects. Successful use of hMSCs will require them to be osteogenically differentiated before transplantation. This study was intended to determine the optimal combination(s) of supplements needed for inducing osteogenesis in hMSCs. Methods: The hMSCs were cultured with combinations of β-glycerophosphate, dexamethasone (Dex), vitamin D3 (Vit-D3), basic fibroblast growth factor (bFGF), and bone morphogenetic protein-2 (BMP-2) to assess cell growth and osteogenesis. Osteogenic responses of the supplements were evaluated by alkaline phosphatase (ALP) activity, mineralization, and gene expression of ALP, Runx2, bone sialoprotein, and osteonectin. Adipogenesis was characterized based on Oil Red O staining, gene expression of peroxisome proliferator-activated receptor γ2, and adipocyte protein-2. Results: Dex was found to be essential for mineralization of hMSCs. Cultures treated with Dex (100 nM), Vit-D3 (10/50 nM), and BMP-2 (500 ng/mL) demonstrated maximal calcification and up-regulation of ALP and bone sialoprotein expression. However, adipogenesis was up-regulated in parallel with osteogenesis in these cultures, as evident by the presence of lipid droplets and significant up-regulation of peroxisome proliferator-activated receptor γ2 and adipocyte protein-2 expression. An optimal condition was obtained at Dex (10 nM) and BMP-2 (500 ng/mL) for mineralization without increasing adipogenesis-related markers. The bFGF mitigated osteogenesis and enhanced adipogenesis. Vit-D3 appears essential for calcification only in the presence of bFGF. Conclusion: Treatment of hMSCs with appropriate supplements at optimal doses results in robust osteogenic differentiation with minimal adipogenesis. These findings could be used in the cultivation of hMSCs for cell-based strategies for bone regeneration.
- Open Access
- 1 October 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (41) , 31590-31602
Rab32 Modulates Apoptosis Onset and Mitochondria-associated Membrane (MAM) Properties
- 1 October 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (41) , 31590-31602
Open AccessRab32 Modulates Apoptosis Onset and Mitochondria-associated Membrane (MAM) Properties